Literature DB >> 16493620

Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin.

Brian R Curtis1, James Kaliszewski, Marisa B Marques, M Wasif Saif, Lisle Nabelle, Jules Blank, Janice G McFarland, Richard H Aster.   

Abstract

Thrombocytopenia developing in the course of chemotherapy for malignant disease is usually attributed to drug-induced marrow suppression and/or marrow replacement by tumor. We describe two patients who developed severe thrombocytopenia and hemorrhagic symptoms while being treated with oxaliplatin, 5-fluorouracil, and leukovorin for metastatic colon cancer in whom platelet destruction appears to have been caused by oxaliplatin-dependent antibodies specific for the platelet glycoprotein IIb/IIIa complex (alpha(IIb)/beta(3) integrin). Drug-induced immune thrombocytopenia (DITP) should be considered in patients who experience a sudden, isolated drop in platelet levels while being treated with chemotherapeutic agents, especially when adequate numbers of megakaryocytes are present in the bone marrow.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493620     DOI: 10.1002/ajh.20516

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  33 in total

1.  Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study.

Authors:  Maarten J Ten Berg; Patricia M L A van den Bemt; Sumitra Shantakumar; Dimitri Bennett; Emile E Voest; Albert Huisman; Wouter W van Solinge; Toine C G Egberts
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

Review 2.  Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature.

Authors:  Marnelli A Bautista; W Tait Stevens; Chien-Shing Chen; Brian R Curtis; Richard H Aster; Chung-Tsen Hsueh
Journal:  J Hematol Oncol       Date:  2010-03-26       Impact factor: 17.388

3.  A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia.

Authors:  Haifaa Dbouk; Simon Mentha; Deborah Mukherji; Jean Lee; Ali Haydar; Ali Shamseddine; Eileen M O'Reilly; Leonard Saltz; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2014-03

4.  Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies.

Authors:  Brian R Curtis; Yen-Michael S Hsu; Nikolai Podoltsev; Jill Lacy; Susanna Curtis; Michael S Samuel; Kristin Zutavern; Robert A DeSimone; Daniel W Bougie; Richard H Aster
Journal:  Blood       Date:  2018-02-12       Impact factor: 22.113

Review 5.  Presentation and Diagnosis of Hypersensitivity to Platinum Drugs.

Authors:  Joana Caiado; Mariana Castells
Journal:  Curr Allergy Asthma Rep       Date:  2015-04       Impact factor: 4.806

6.  A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study.

Authors:  Orren Beaty; Stacey Berg; Susan Blaney; Marcio Malogolowkin; Mark Krailo; Ronald Knight; Paula Schaiquevich; Clinton Stewart; Zhengjia Chen; Marvin Nelson; Stephan Voss; S Percy Ivy; Peter C Adamson
Journal:  Pediatr Blood Cancer       Date:  2010-09       Impact factor: 3.167

Review 7.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

Review 8.  Drug-induced thrombocytopenia: pathogenesis, evaluation, and management.

Authors:  James N George; Richard H Aster
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

9.  Oxaliplatin induced disseminated intravascular coagulation: A case report and review of literature.

Authors:  Shweta Kurian; Jessica Macintyre; Muzammil Mushtaq; Caio Max Rocha-Lima; Yeon Ahn
Journal:  World J Gastrointest Oncol       Date:  2012-07-15

Review 10.  Drug-induced thrombocytopenia.

Authors:  Gian Paolo Visentin; Chao Yan Liu
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.